SP100 and primary biliary cholangitis: Gatselis et al.18conducted a 3‐year follow‐up of 14 anti‐sp100 antibody‐positive PBC patients and showed that reduced anti‐sp100 titers were associated with improved Mayo risk score and UDCA response.